Nutraseb Available for the Management of Seborrheic Dermatitis

A clinical trial of Promiseb (NCT01214434) found the cream to be safe and significantly efficacious in reducing scaling from baseline to end of treatment when compared with a bland emollient (58%; SD: 62 vs. 90%; SD: 22).

Nutraseb Facial Cream (ISDIN) has been made available for the management of seborrhea and seborrheic dermatitis.

Nutraseb is a steroid-free, fragrance-free, water-based emulsion that is indicated to manage and relieve the signs and symptoms of seborrhea and seborrheic dermatitis, such as itching, erythema, scaling, and pain. It helps to relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

In a clinical trial evaluating the efficacy of Nutraseb for the treatment of mild facial seborrheic dermatitis, a significant number of patients using Nutraseb saw a reduction in erythema; 78.8% of patients reported that the cream was “good” or “excellent”. 

The safety and effectiveness of Nutraseb has not been tested on patients younger than 22 years old.

Related Articles

The product is available by prescription and is supplied as two 50g tubes in a single carton.

“The ISDIN brand is an emerging skincare staple in the US market leveraging our longstanding reputation in Spain and is pleased to be launching our very first prescription product in the US,” said Robert D’Urso, US Country Manager of ISDIN.

For more information visit